Publications by authors named "C Guillen-Ponce"
Background: BRCA1/2 genes play a critical role in genome stability and DNA repair. In animal models, loss of cardiomyocyte-specific BRCA1/2 is associated with DNA damage, apoptosis, cardiac dysfunction, and mortality following anthracycline exposure. However, whether these preclinical findings translate to humans remains unclear.
View Article and Find Full Text PDFPurpose: Pancreatic adenocarcinoma (PDAC) has limited treatment options. We compared the efficacy of comprehensive precision medicine against the conventional treatment in PDAC.
Methods: Phase III trial of advanced PDAC where patients were randomized (1:2) to a conventional treatment treated at physician's discretion (arm A), or to precision medicine (arm B).
Article Synopsis
- Among the other affected relatives, one has ovarian cysts and thyroid issues, while the rest have multinodular goiter; a deceased sister had multiple ovarian and thyroid cancers.
- This suggests the gene in question should be evaluated in families with similar cancer backgrounds, contributing to understanding how it relates to hereditary breast and ovarian cancer syndromes.
Article Synopsis
- RAD51C and RAD51D genes play a crucial role in DNA repair, and mutations in these genes significantly increase the risk of developing ovarian and breast cancer.
- This study analyzed the clinical characteristics of 91 patients and 90 relatives with pathogenic variants in RAD51C/D across multiple Spanish hospitals, focusing on their tumors' homologous recombination deficiency (HRD) status.
- Findings showed that a substantial portion of the carriers were women, with a high incidence of breast and ovarian cancer; the study also determined the prevalence of HRD in untreated tumors from these patients.
BACKGROUND: Sequential nab-paclitaxel plus gemcitabine followed by modified FOLFOX-6 (oxaliplatin, leucovorin, and 5-fluorouracil) (nab-P/Gem-mFOLFOX) showed a good safety and clinical profile in metastatic pancreatic ductal adenocarcinoma (mPDAC) in the phase I SEQUENCE trial. METHODS: The safety and efficacy of sequential nab-P/Gem-mFOLFOX was compared with standard nab-paclitaxel plus gemcitabine (nab-P/Gem) as first-line treatment in a multi-institutional, randomized, open-label, phase II trial in patients with untreated mPDAC. We randomly assigned patients in a 1:1 ratio to receive nab-P/Gem on days 1, 8, and 15 followed by mFOLFOX on day 29 of a 6-week cycle (experimental group) or nab-P/Gem on days 1, 8, and 15 of a 4-week cycle (control group).
View Article and Find Full Text PDF